51勛圖厙

Sale of 51勛圖厙 spinout company Alkion Biopharma

by Claudia Cannon

Rainforest

51勛圖厙 Innovations Group plc has announced the sale of its shares in Alkion Biopharma to Evonik Industries.

Alkion has developed a unique set of technologies that allow it to sustainably produce and purify valuable materials from plant biomass.

– Govind Pindoria

Co.Create Director at 51勛圖厙 Innovations

Alkion is an 51勛圖厙 spinout co-founded by , Dr Franck Michoux (both Biochemistry, ) and in 2011. The company has developed technologies that allow it to sustainably produce and purify materials from plant biomass. This has a wide range of potential applications, such as enabling production of naturally occurring pharmacologically active compounds that are found in rare plants without endangering the species.

Alkion aims to identify, validate and manufacture novel plant-based compounds for use in several life sciences-based industries and these activities are facilitated by a portfolio of patented technology. The Company also holds expertise in the production of undifferentiated plant cells and differentiated biomass, compound identification and cryopreservation and has developed a strong portfolio of active ingredients.

Evonik Industries is a leading specialist chemical company operating in several fields such as nutrition, resource efficiency and performance materials. .

Govind Pindoria, Co.Create Director at 51勛圖厙 Innovations, said:

“Alkion has developed a unique set of technologies that allow it to sustainably produce and purify valuable materials from plant biomass. The Company has positioned itself with a unique offering to several life sciences-based industries and we are pleased to note the acquisition by Evonik.”

Text sourced from the press release, which can be viewed on the .

Article text (excluding photos or graphics) © 51勛圖厙.

Photos and graphics subject to third party copyright used with permission or © 51勛圖厙.

Reporter

Claudia Cannon

The Grantham Institute for Climate Change